Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors (Q37446311)
scientific article published on 03 January 2014
Language:
(P31) (Q13442814)
(P50) (Q92127474)
(Q43249916)
(P304) 1
(P407) (Q1860)
(P478) 7
(P577) Friday, January 3, 2014
(P921) (Q5452194)
(Q181600)
(Q25100065)
(Q420436)
(Q418369)
(P953) https://jhoonline.biomedcentral.com/counter/pdf/10.1186/1756-8722-7-1
https://europepmc.org/articles/PMC3884022
https://europepmc.org/articles/PMC3884022?pdf=render
http://link.springer.com/content/pdf/10.1186/1756-8722-7-1.pdf
(P1433) (Q15724593)
(P1476) "Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors" (language: en)
(P2093) Li Yan
Joanna Vitfell-Rasmussen
Eric Chen
Andrea Biondo
Ernestina Tetteh
Amita Patnaik
Susan Minton
L. Rhoda Molife
Adriane M. Zernhelt
Daniel M. Sullivan
Philippe A. Cassier
Lillian L. Siu
Kyriakos P. Papadopoulos
Anthony W. Tolcher
(P2860) (Q28484970)
(Q34275011)
(Q27851678)
(Q37705534)
(Q24632283)
(Q37564760)
(Q29617685)
(Q27851457)
(Q37250036)
(Q36320600)
(Q34308421)
(Q35046899)
(Q34389540)
(Q33180222)
(Q27860904)
(Q29618387)
(Q38431323)
(Q39847621)
(Q40110221)
(Q40265324)
(Q42504535)
(Q51907391)
(Q46803921)
(Q45271704)
(Q44246942)
(Q35170212)
(Q83066772)
other details
description scientific article published on 03 January 2014

External Links